AIP
MRTX

Ameritas Investment Partners’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Ameritas Investment Partners’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,530
Closed -$605K – 3273
2021
Q1 		$605K Sell
3,530
-84
-2% -$16.6K 0.02% 738
2020
Q4 		$794K Buy
3,614
+366
+11% +$79.1K 0.04% 634
2020
Q3 		$539K Hold
3,248
– – 0.02% 701
2020
Q2 		$371K Buy
3,248
+660
+26% +$64K 0.02% 787
2020
Q1 		$199K Buy
2,588
+215
+9% +$19.3K 0.01% 939
2019
Q4 		$306K Buy
2,373
+108
+5% +$10.4K 0.01% 881
2019
Q3 		$176K Buy
2,265
+132
+6% +$12.4K 0.01% 1123
2019
Q2 		$220K Buy
2,133
+366
+21% +$28.5K 0.01% 1008
2019
Q1 		$130K Buy
1,767
+201
+13% +$13.7K 0.01% 1311
2018
Q4 		$66K Hold
1,566
– – ﹤0.01% 1655
2018
Q3 		$74K Buy
1,566
+150
+11% +$8.35K ﹤0.01% 1750
2018
Q2 		$70K Buy
+1,416
New +$53.5K ﹤0.01% 1786
2017
Q2 		– Sell
-893
Closed -$5K – 3065
2017
Q1 		$5K Buy
+893
New +$4.89K ﹤0.01% 2851

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Ameritas Investment Partners's MRTX Position: Q2 2021 in Review

Ameritas Investment Partners sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2021, closing a stake of 3,530 shares — an estimated $605K sold.

Ameritas Investment Partners first reported a position in MRTX in Q1 2017 and held it in 13 quarters. The position peaked at $794K in Q4 2020. 245 funds tracked by Wall St. Rank hold MRTX as of Q2 2021.

  • Ameritas Investment Partners reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Ameritas Investment Partners sold 3,530 Mirati Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $605K.
  • Ameritas Investment Partners first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2017 and held it in 13 quarters.
  • Ameritas Investment Partners's Mirati Therapeutics, Inc. Common Stock position peaked at $794K in Q4 2020.
  • 245 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Ameritas Investment Partners's 13F filing for Q2 2021, filed 6 Aug 2021.